Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†
Why the study?
Does edoxaban reduce stroke or systemic embolic events compared to warfarin in VKA-naive versus VKA-experienced patients with atrial fibrillation?
Population
21,105 patients with atrial fibrillation at moderate-to-high risk of stroke, analyzed by prior vitamin K…
Comparison
Edoxaban vs Warfarin
Design
RCT, randomized
Follow-up
median 2.8 years
Authors
Discussion
Loading...
Member takes
Implication
Favors higher-dose edoxaban over warfarin in VKA-naive AF; extends randomized evidence by revealing efficacy interaction with prior VKA exposure.
Structured PICO
Does edoxaban reduce stroke or systemic embolic events compared to warfarin in VKA-naive versus VKA-experienced patients with atrial fibrillation?
P
Population
21,105 patients with atrial fibrillation at moderate-to-high risk of stroke, analyzed by prior vitamin K antagonist (VKA) experience (>60 consecutive days) versus VKA naive
I
Intervention
Edoxaban (higher-dose and lower-dose regimens, oral once-daily)
C
Comparator
Warfarin
O
Outcome
Stroke or systemic embolic event (SEE)composite
Higher-dose edoxaban provides greater stroke and systemic embolism protection compared to warfarin in VKA-naive patients, while maintaining a consistent reduction in major bleeding regardless of prior VKA exposure.
Cite This Study
O’Donoghue et al. (2015) studied this question.